Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.19.3
REVENUES
9 Months Ended
Sep. 30, 2019
Revenue From Contract With Customer [Abstract]  
REVENUES

NOTE 3 — REVENUES

Revenues disaggregated by category were as follows (in thousands):

 

 

Three Months Ended September 30, 2019

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Endari®

 

$

5,994

 

 

$

4,803

 

 

$

16,960

 

 

$

7,863

 

Other

 

 

90

 

 

$

79

 

 

 

300

 

 

 

372

 

Revenues, net

 

 

6,084

 

 

 

4,882

 

 

 

17,260

 

 

 

8,235

 

 

The following table summarizes the revenue allowance and accrual activities for the nine months ended September 30, 2019 (in thousands):

 

 

Trade Discounts, Allowances and Chargebacks

 

 

Government Rebates and Other Incentives

 

 

Returns

 

 

Total

 

Balance as of December 31, 2018

 

$

303

 

 

$

1,880

 

 

$

181

 

 

$

2,364

 

Provision related to sales in the current year

 

 

1,039

 

 

 

2,368

 

 

 

190

 

 

 

3,597

 

Adjustments related prior period sales

 

 

(218

)

 

 

(1,082

)

 

 

 

 

 

(1,300

)

Credit and payments made

 

 

(866

)

 

 

(1,816

)

 

 

 

 

 

(2,682

)

Balance as of September 30, 2019

 

$

258

 

 

$

1,350

 

 

$

371

 

 

$

1,979

 

The following table summarizes revenues attributable to each of our customers who accounted for 10% or more of our total revenues (as a percentage of total revenues):

 

 

Three Months Ended September 30, 2019

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

AmerisourceBergen Specialty Group

 

 

62

%

 

 

90

%

 

 

60

%

 

 

88

%

McKesson Plasma and Biologics LLC

 

 

22

%

 

 

4

%

 

 

21

%

 

 

3

%